LÁBR, Karel, Jindřich ŠPINAR, Jiří PAŘENICA, Lenka ŠPINAROVÁ, F. MÁLEK, Monika ŠPINAROVÁ, Ondřej LUDKA, Jiří JARKOVSKÝ, Klára BENEŠOVÁ and Růžena LÁBROVÁ. Betablokátory v registru chronického srdečního selhání FAR NHL (Beta-blockers in chronic heart failure as recorded in the FAR NHL registr). Kardiologická revue - Interní medicína. Praha: Ambit Media, 2017, vol. 19, No 1, p. 68-72. ISSN 1212-4540.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Betablokátory v registru chronického srdečního selhání FAR NHL
Name in Czech Betablokátory v registru chronického srdečního selhání FAR NHL
Name (in English) Beta-blockers in chronic heart failure as recorded in the FAR NHL registr
Authors LÁBR, Karel (203 Czech Republic, belonging to the institution), Jindřich ŠPINAR (203 Czech Republic, belonging to the institution), Jiří PAŘENICA (203 Czech Republic, belonging to the institution), Lenka ŠPINAROVÁ (203 Czech Republic, belonging to the institution), F. MÁLEK (203 Czech Republic), Monika ŠPINAROVÁ (203 Czech Republic, belonging to the institution), Ondřej LUDKA (203 Czech Republic, belonging to the institution), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Klára BENEŠOVÁ (203 Czech Republic, belonging to the institution) and Růžena LÁBROVÁ (203 Czech Republic, guarantor, belonging to the institution).
Edition Kardiologická revue - Interní medicína, Praha, Ambit Media, 2017, 1212-4540.
Other information
Original language Czech
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14110/17:00098136
Organization unit Faculty of Medicine
Keywords (in Czech) betablokátory; srdeční selhání; NT-proBNP; krevní tlak; farmakoterapie; ejekční frakce levé komory; kreatininová clearance
Keywords in English adrenergic beta-antagonists; heart failure; pro-brain natriuretic peptide; blood pressure
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 22/3/2018 15:39.
Abstract
Úvod: Betablokátory (BB) jsou lékem první volby společně s inhibitory angiotenzin konvertujícího enzymu (ACEI) nebo blokátorů receptorů pro angiotenzin II (ARB) u pacientů se srdečním selháním se sníženou ejekční frakcí levé komory (heart failure with reduced ejection fraction – HFrEF), snižují morbiditu i mortalitu. Metodika: Data byla sbírána v rámci registru FARmakologie a NeuroHumoráLní aktivace (FAR NHL). Zařazeni byli alespoň měsíc stabilní pacienti s chronickým srdečním selháním s ejekční frakcí levé komory (EF LK) < 50 %.
Abstract (in English)
Background: Beta-blockers (BB) and angiotensin-converting-enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARB) are part of the first-line treatment of heart failure with reduced ejection fraction (HFrEF), leading to decreased morbidity and mortality. Methods: The data were collected from the Pharmacology and l Neurohumoral Activation Registry (FAR NHL). Patients with left ventricle ejection fraction (LV EF) under 50% who were stable for at least one month were included. Results: A total of 1,100 patients were included, median age was 65 years, 80.8% were male. Of all patients, 20% received low dose (LD), 57% medium dose (MD) and 17% high dose (HD). Of these, 6.2% of patients were not treated with BBs at all. The higher the blood pressure (BP; LD 124/77; MD 129/80; HD 132/82 mm Hg, p < 0.001), LV EF (LD 29.5; MD 30.5; HD 32.0%; p = 0.003), creatinine clearance rate (CrCl; LD 78.7; MD 87.8; HD 91.1 ml/min; p = 0.001) or body weight (LD 83.2; MD 88.7; HD 93.5 kg; p < 0.001) was, the higher the dose of BB they received. The lower the NT-proBNP level was, the higher the dose of BB they received (LD 767; MD 456; HD 314 pg/ml; p < 0.001). There was no difference in prescription of BB depending on the presence of atrial fibrillation (AF). Patients with AF were more often treated with digoxin or a combination of digoxin and BB than patients without AF (p < 0.001). Summary: Nearly 94% of HFrEF patients received BB, but only 17% received the target dose of BB. Ninety-nine % of patients treated with BB received one of the drugs recommended by the ESC Guidelines. The more severe the illness was, as expressed by lower BP, CrCl, LV EF, body weight and higher NT-proBNP, the lower the dose of BB the patients received and tolerated.
Links
MUNI/A/1270/2015, interní kód MUName: Význam bioptické diagnostiky u nově vzniklé dilatační kardiomyopatie
Investor: Masaryk University, Category A
PrintDisplayed: 30/5/2024 04:56